Hironari Hanaoka (H Hanaoka)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 18

Top Topics

Disease Activity

Antiplatelet Therapy

Systemic Lupus Erythematosus

Angiotensin Converting Enzyme

Top Venues

International journal of rheumatic diseases

Immunological medicine

Clinical rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Jun Kikuchi, Yasushi Kondo, Shuichiro Kojima, Shiho Kasai, Yuma Sakai, Masaru Takeshita, Kazuoto Hiramoto, Shuntaro Saito, Hiroyuki Fukui, Hironari Hanaoka, Katsuya Suzuki, Yuko Kaneko
Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus. Immunological medicine (2024)
Jun Kikuchi, Yasushi Kondo, Shuichiro Kojima, Shiho Kasai, Yuma Sakai, Masaru Takeshita, Kazuoto Hiramoto, Shuntaro Saito, Hiroyuki Fukui, Hironari Hanaoka, Katsuya Suzuki, Yuko Kaneko
Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus. Immunological medicine 47 (2) (2024)
Jun Kikuchi, Yasushi Kondo, Shuichiro Kojima, Shiho Kasai, Yuma Sakai, Masaru Takeshita, Kazuoto Hiramoto, Shuntaro Saito, Hiroyuki Fukui, Hironari Hanaoka, Katsuya Suzuki, Yuko Kaneko
Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus. Immunological medicine 47 (2) (2024)
Hironari Hanaoka, Jun Kikuchi, Kazuoto Hiramoto, Mitsuhiro Akiyama, Shutaro Saito, Yasushi Kondo, Yuko Kaneko
Sarcopenia in patients with rheumatic musculoskeletal diseases. International journal of rheumatic diseases (2023)
Satoshi Takanashi, Yasushi Kondo, Shuntaro Saito, Jun Kikuchi, Hironari Hanaoka, Tsutomu Takeuchi, Yuko Kaneko
Effectiveness and safety of rituximab in special types of rheumatoid arthritis. International journal of rheumatic diseases (2023)
Hironari Hanaoka, Jun Kikuchi, Kazuoto Hiramoto, Shuntaro Saito, Yasushi Kondo, Yuko Kaneko
Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs. Clinical kidney journal 15 (7) (2022)
Christopher A Mecoli, Akira Yoshida, Julie J Paik, Cheng Ting Lin, Sonye Danoff, Hironari Hanaoka, Antony Rosen, Lisa Christopher-Stine, Masataka Kuwana, Livia A Casciola-Rosen
Presence and Implications of Anti-Angiotensin Converting Enzyme-2 Immunoglobulin M Antibodies in Anti-Melanoma-Differentiation-Associated 5 Dermatomyositis. ACR open rheumatology 4 (5) (2022)
Jun Kikuchi, Hironari Hanaoka, Shuntaro Saito, Tatsuhiro Oshige, Kazuoto Hiramoto, Yuko Kaneko, Tsutomu Takeuchi
Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus. Rheumatology (Oxford, England) 61 (9) (2022)
Hironari Hanaoka, Sho Ishigaki, Hiroshi Takei, Kazuoto Hiramoto, Shuntaro Saito, Yasushi Kondo, Jun Kikuchi, Yuko Kaneko, Tsutomu Takeuchi
Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue disease-associated pulmonary hypertension. International journal of rheumatic diseases 24 (11) (2021)
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa, Kimito Kawahata
Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations. Clinical rheumatology 38 (10) (2019)
Yukiko Takakuwa, Hironari Hanaoka, Tomofumi Kiyokawa, Harunobu Iida, Hisae Fujimoto, Yoshioki Yamasaki, Hidehiro Yamada, Kimito Kawahata
Low-dose rituximab as induction therapy for ANCA-associated vasculitis. Clinical rheumatology 38 (4) (2019)
Tomofumi Kiyokawa, Hironari Hanaoka, Harunobu Iida, Kana Ishimori, Yukiko Takakuwa, Takahiro Okazaki, Shoichi Ozaki, Kimito Kawahata
High plasma mycophenolate acid concentration in the early phase of induction therapy predicts good renal outcome in lupus nephritis. Modern rheumatology 30 (3) (2019)
Harunobu Iida, Hironari Hanaoka, Yukinori Okada, Tomofumi Kiyokawa, Yukiko Takakuwa, Hidehiro Yamada, Takahiro Okazaki, Shoichi Ozaki, Kenichiro Yamaguchi, Yasuo Nakajima, Kimito Kawahata
A low perfusion-metabolic mismatch in 99m Tl and 123 I-BMIPP scintigraphy predicts poor prognosis in systemic sclerosis patients with asymptomatic cardiac involvement. International journal of rheumatic diseases 22 (6) (2019)
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa, Kimito Kawahata
Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy. Clinical rheumatology 38 (2) (2018)
Hironari Hanaoka, H Iida, T Kiyokawa, Y Takakuwa, K Kawahata
A positive direct Coombs' test in the absence of hemolytic anemia predicts high disease activity and poor renal response in systemic lupus erythematosus. Lupus 27 (14) (2018)
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa, Kimito Kawahata
Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor. International journal of rheumatic diseases 22 (3) (2018)
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa, Takahiro Okazaki, Hidehiro Yamada, Shoichi Ozaki, Kimito Kawahata
Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome. PloS one 13 (5) (2018)
Hironari Hanaoka, Tomofumi Kiyokawa, Harunobu Iida, Kana Ishimori, Yukiko Takakuwa, Takahiro Okazaki, Hidehiro Yamada, Daisuke Ichikawa, Sayuri Shirai, Junki Koike, Shoichi Ozaki
Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV: A single-centre retrospective study. PloS one 12 (4) (2017)